[The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
Patients with multiple sclerosis receiving interferon beta (IFN) may develop neutralizing anti-interferon beta antibodies (NABs). The importance of NABs has not been completely explained, however it is generally reckoned that they might be one of the factors diminishing treatment efficacy. This paper presents the consequences of NABs formation during IFN therapy. Differences of immunogenicity between the interferon beta products with regard to their structure, formulation, dose, route of administration were presented and the influence of NABs on the biological and clinical activity of IFN beta therapy was shown.
Bartosik-Psujek
Halina
H
Katedra i Klinika Neurologii, Akademia Medyczna, ul. Jaczewskiego 8, 20-954 Lublin. halbp@poczta.onet.pl
Stelmasiak
Zbigniew
Z
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000906:Antibodies / Q000276:immunology*; D000917:Antibody Formation / Q000502:physiology; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D016899:Interferon-beta / Q000276:immunology* / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000906:Antibodies; D016899:Interferon-beta